Literature DB >> 7706161

High prevalence of antifungal resistance in Candida spp. from patients with AIDS.

D Law1, C B Moore, H M Wardle, L A Ganguli, M G Keaney, D W Denning.   

Abstract

Three hundred and forty-eight isolates of Candida spp. from patients treated at a regional infectious diseases unit for AIDS, immunocompromised patients admitted to the Hope Hospital and isolates referred from around the North West of England were tested for their in-vitro susceptibility to amphotericin B, fluconazole and flucytosine using standardized methods. Candida albicans comprised 73% of isolates, Candida glabrata 10% and Candida parapsilosis 7%. Ninety-six percent of isolates were susceptible to amphotericin B and resistance to > or = 12.5 mg/L fluconazole was found in 61 (17.5%) of the 348 isolates tested. Among isolates from patients with AIDS the incidence of fluconazole resistance was 33% whereas in other patients the incidence was only 11%. Flucytosine resistance was seen in only 12 (3.4%) isolates, 11 of which were C. albicans and in 6.5% of isolates from patients with AIDS. Resistance to fluconazole and flucytosine is now sufficiently prevalent among Candida spp. isolated from patients with AIDS to warrant routine susceptibility testing of yeast isolates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7706161     DOI: 10.1093/jac/34.5.659

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  40 in total

1.  Transcriptional analyses of antifungal drug resistance in Candida albicans.

Authors:  C N Lyons; T C White
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.

Authors:  Yasuki Kamai; Masayo Kakuta; Takahiro Shibayama; Takashi Fukuoka; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United kingdom mycology reference laboratory.

Authors:  Christopher J Linton; Andrew M Borman; Grace Cheung; Ann D Holmes; Adrien Szekely; Michael D Palmer; Paul D Bridge; Colin K Campbell; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

4.  Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors.

Authors:  K W Henry; J T Nickels; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I study.

Authors:  S De Wit; E O'Doherty; J Edwards; R Yates; R P Smith; A N Clumeck
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

Authors:  D Law; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.

Authors:  H M Wardle; D Law; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

8.  Susceptibilities of oral bacteria and yeast to mammalian cathelicidins.

Authors:  J M Guthmiller; K G Vargas; R Srikantha; L L Schomberg; P L Weistroffer; P B McCray; B F Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Comparison of the API Candida system with the AUXACOLOR system for identification of common yeast pathogens.

Authors:  C K Campbell; K G Davey; A D Holmes; A Szekely; D W Warnock
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Multilocus sequence typing of Candida glabrata reveals geographically enriched clades.

Authors:  Andrew R Dodgson; Claude Pujol; David W Denning; David R Soll; Andrew J Fox
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.